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To detect early cases of pandemic (H1N1) 2009 infec-
tion, in 2009 we surveyed 303 persons from marginalized 
populations of drug users, sex workers, and homeless per-
sons in Tijuana, Mexico. Six conﬁ  rmed cases of pandemic 
(H1N1) 2009 were detected, and the use of rapid, mobile 
inﬂ  uenza testing was demonstrated.
T
he ﬁ  rst declared inﬂ  uenza pandemic in 40 years like-
ly originated in March 2009 in La Gloria, Veracruz, 
a small rural town in southern Mexico (1). The virus re-
sponsible for the outbreak, identiﬁ  ed as a novel inﬂ  uenza A 
(H1N1) virus, now referred to as pandemic (H1N1) 2009, 
spread quickly. By the end of 2009, ≈70,000 cases were 
conﬁ  rmed and 944 deaths were recorded in Mexico (2), and 
>600,000 cases were reported worldwide (3).
When pandemic (H1N1) 2009 ﬁ  rst emerged there was 
concern that Mexico–US border cities, which have served 
as corridors for binational transmission of infectious dis-
eases (4), might become overwhelmed by the disease be-
fore national surveillance resources could be mobilized. 
Of particular concern was the fact that traditional hospi-
tal-based disease surveillance would miss the emergence 
of pandemic (H1N1) 2009 in the dense, highly mobile (5), 
marginalized border populations. Furthermore, the poor-
est and most underserved border populations, composed 
of the homeless, commercial sex workers, and those with 
alcohol and drug abuse problems, have disproportionately 
high levels of diseases such as HIV (6) and tuberculo-
sis (7), illnesses suspected of increasing vulnerability 
to acquiring and dying of pandemic (H1N1) 2009 (8,9). 
We report the results of an enhanced surveillance effort 
to detect early pandemic (H1N1) 2009 cases and assess 
perceptions of the pandemic and risk factors associated 
with acquiring the disease in marginalized populations in 
Tijuana, Mexico. 
The Study 
This surveillance project was a collaboration between 
Mexican public health ofﬁ  cials, nongovernment organiza-
tions, and the University of California, San Diego (UCSD). 
The project was approved by the institutional review boards 
of Tijuana General Hospital and UCSD.
Our binational research team of US and Mexican 
researchers has been conducting prospective studies of 
populations at high risk for infectious diseases in the most 
vulnerable communities of Tijuana and Ciudad Juarez, 
Mexico, since 2004 (10,11). More than 2,500 drug users, 
sex workers, and homeless persons have been recruited to 
participate in those studies. From May 1 through Novem-
ber 20, 2009, we conducted active and passive inﬂ  uenza 
surveillance within our existing marginalized study popu-
lations in Tijuana. We used mobile outreach units and com-
munity clinics in the city’s Zona Roja (red light zone) as 
magnet sites (Figure).
Active surveillance included contacting all known cur-
rent and previous study participants, parking mobile health 
units in study zones (Figure), and having outreach workers 
refer persons who reported feeling unwell for any reason. 
Passive recruitment, conducted by word-of-mouth adver-
tising, was open to all persons in communities served by 
our mobile and ﬁ  xed-site clinics.
Persons seen by the surveillance team had their oral 
temperatures recorded and completed brief surveys docu-
menting demographics, inﬂ  uenza risk factors, and clinical 
symptoms. Persons meeting inclusion criteria for inﬂ  uen-
za-like illness based on early Centers for Disease Control 
and Prevention guidelines (12) were considered pandemic 
(H1N1) 2009 suspected case-patients. Inclusion crite-
ria were a subjective or objective fever (oral temperature 
>100°F [37.8°C]) and 1 of the following signs or symp-
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toms: cough, sore throat, severe headache, diarrhea, vomit-
ing, or severe muscle/body aches and fatigue.
Persons with inﬂ  uenza-like illness completed an in-
depth survey and underwent rapid inﬂ  uenza testing. Partic-
ipants were compensated $5 US. In-depth surveys included 
questions on symptom duration, treatment choices, and 
pandemic (H1N1) 2009 knowledge.
Enrolled pandemic (H1N1) 2009 suspected case-pa-
tients provided a nasopharyngeal swab for rapid inﬂ  uenza 
testing with the BinaxNOW assay (Inverness Medical, 
Waltham, MA, USA). Suspected case-patients with posi-
tive rapid test results for type A inﬂ  uenza were considered 
probable pandemic (H1N1) 2009 case-patients and pro-
vided another nasopharyngeal swab for inﬂ  uenza A strain 
conﬁ  rmation and characterization. Persons with positive 
test results were transported to Tijuana General Hospi-
tal for evaluation and treatment. Suspected case-patients 
with negative rapid inﬂ  uenza test results were not evalu-
ated further.
Nasal swab specimens were cultured on MDCK cells 
within 48 hours of ﬁ  eld collection. Positive cultures were 
detected by cytopathic effect and by hemabsorbtion. Vi-
ral isolates were characterized by hemagglutinin and 
neuraminidase type by using immunoﬂ  uorescent staining 
(ViroStat, Portland, ME, USA and eEnzyme, Gaithersburg, 
MD, USA) and conﬁ  rmed to be pandemic (H1N1) 2009 by 
real-time PCR (13).
From May 1 through November 20, 2009, a total of 
303 persons were screened. Forty-three (15%) met inclu-
sion criteria as pandemic (H1N1) 2009 suspected case-pa-
tients and were tested with the rapid inﬂ  uenza test. Six sus-
pected case-patients (14%) had rapid test results positive 
for inﬂ  uenza A, and all 6 were conﬁ  rmed to have inﬂ  uenza 
A pandemic (H1N1) 2009 virus. One patient had a rapid 
test result positive for inﬂ  uenza B. Pandemic (H1N1) 2009 
cases were not related and were detected at a rate of ≈1/ 
month during July–November.
Median age of screened persons was 35 years (in-
terquartile range 29–43 years), and 62% were men 
(Table). Median oral temperature of patients with con-
ﬁ  rmed pandemic (H1N1) 2009 was 37.9°C (IRQ 37–38.3). 
Six (86%) of 7 patients with inﬂ  uenza reported a cough 
and 5 (71%) reported sore throat or severe joint/muscle 
ache. Less than 10% of screened persons not identiﬁ  ed 
as inﬂ  uenza suspected case-patients had these symptoms. 
No patients with conﬁ  rmed inﬂ  uenza reported vomiting 
or diarrhea.
All patients with conﬁ  rmed pandemic (H1N1) 2009 
received antiviral drug treatment within 24 hours of their 
positive rapid inﬂ  uenza test result; no pandemic (H1N1) 
2009 related deaths were reported by completion of the 
study. One person with a negative rapid test result who was 
severely ill during the survey died within days of being re-
ferred to Tijuana General Hospital but was diagnosed with 
end-stage tuberculosis after death, not inﬂ  uenza.
Awareness was high; 88% of screened persons (n = 
264/300) who answered the question about prior knowl-
edge reported hearing about the pandemic (H1N1) 2009 
epidemic in Mexico before the time of screening. More 
than 80% heard about the epidemic from television broad-
casts. All pandemic (H1N1) 2009 suspected case-patients 
(n = 43) reported that they would get a pandemic (H1N1) 
2009 vaccine if available; most suspected case-patients 
(71%) preferred to be vaccinated in a hospital.
Conclusions
Of ≈1,200 persons and their families who were con-
tacted directly during the course of this survey, 303 self-
identiﬁ  ed as “feeling unwell” during May 1–November 20, 
2009. Six persons had conﬁ  rmed pandemic (H1N1) 2009 
virus, but given that the rapid inﬂ  uenza test used for screen-
ing in this study has only moderate sensitivity (14), this is 
likely an underestimate of cases. Conﬁ  rmed cases repre-
sented ≈0.7% of the 826 pandemic (H1N1) 2009 cases re-
corded in Tijuana during April–November 2009 (15), sug-
gesting that isolation of these populations from the general 
population might have been protective.
All case-patients were treated with antiviral medica-
tion within 24 hours of a rapid inﬂ  uenza A positive test 
result, but access to antiviral drugs was through nontradi-
tional means requiring many levels of negotiation by study 
staff and medical professionals in Tijuana that would not 
have been practical if more cases had been detected. The 
antiviral medication, oseltamivir, although plentiful in the 
United States, was only available in limited quantities in 
Tijuana, indicating that there are major hurdles to over-
come in binational distribution of medical resources in an 
early pandemic setting.
Although rapid inﬂ  uenza tests are relatively insensitive, 
especially for pandemic (H1N1) 2009 (14), these tests can 
identify persons for PCR conﬁ  rmation in an efﬁ  cient and 
cost-effective fashion for early detection of cases. If pan-
demic (H1N1) 2009 were to develop more extensively in 
this population, changing inclusion criteria to objective fe-
ver (>100°F [37.8°C]) plus sore throat and/or cough would 
likely be effective for identifying pandemic (H1N1) 2009 
cases with greater precision. Despite the limited health, ﬁ  -
nancial resources, and unstable housing in our study popu-
lation, it appears that television broadcasts were effective 
in distributing early messages about pandemic (H1N1) 
2009. This enhanced surveillance survey, planned and ex-
ecuted safely and efﬁ  ciently within 4–6 weeks of the initial 
pandemic (H1N1) 2009 cases in Mexico, demonstrated the 
potential of binational academic/public health collabora-
tions to respond to emerging health threats in Mexico/US 
border regions in real time.
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